Redefining clinical trials in oncology and rare diseases across the Europe
Later this month, experts from the pharmaceutical and biotechnology industry and patient advocacy space will gather in Munich, Germany, to …
Post
-
-
The changing dynamics of eClinical: Why configurability is king
Clinical trial sponsors are navigating a landscape of increasing complexity. A team of researchers recently set out to explore this …
-
Acumen doses first subject in Phase II OLE segment of Alzheimer’s therapy
Acumen Pharmaceuticals has dosed the first subject in the open-label extension (OLE) segment of its Phase II Altitude-AD trial of …
-
Nuvalent aiming for approval on pivotal trial data for NSCLC candidate
Nuvalent’s stock price oscillated after it’s investigational ALK-selective inhibitor showed promise in patients with advanced ALK-positive non-small cell lung cancer …
-
Roche reports positive Phase III data of giredestrant for breast cancer
Roche has reported encouraging outcomes from its Phase III lidERA Breast Cancer trial of oral giredestrant as an adjuvant endocrine …
-
Proper implementation of technology vital for efficient data management
As AI and technology are changing the way clinical trial data is managed, the next question is how this should …
-
ReCode initiates Phase II trial of RCT2100 with ivacaftor for CF
ReCode Therapeutics has initiated the third part of its Phase II clinical trial of the inhaled cystic fibrosis transmembrane conductance …
-
Measles-free status of Canada revoked
On 10 November 2025, the revocation of Canada's measles elimination status was announced by the Pan American Health Organization (PAHO). …
-
Clinical Trials Arena Excellence Awards 2025: Novotech
Novotech, a global full-service contract research organization, won the Research and Development and Marketing awards in the 2025 Clinical Trials …
-
Agomab’s ALK5 inhibitor to advance to Phase IIb in Crohn’s disease
Agomab Therapeutics is taking its lead candidate, ontunisertib, to a Phase IIb trial following its mid-stage success in fibrostenosing Crohn’s …
-
BMS and Johnson & Johnson terminate Phase III ACS trial due to likely failure
Editor’s note: This article has been updated to clarify that the collaboration was with Johnson & Johnson, not AstraZeneca as …
-
Cancer Research UK to initiate lung cancer preventative vaccine trial
Cancer Research UK is set to initiate a trial of a vaccine aimed at preventing lung cancer in patients at …
-
Samson Clinical concludes enrolment for Phase III AGA trial
Samson Clinical has concluded participant enrolment for its SAM-002 Phase III clinical trial assessing sublingual minoxidil in male pattern hair …
-
Digital twins for clinical trials: early days, rapid momentum
In recent years, automation and artificial intelligence (AI) have been huge trends within the clinical trials landscape, as companies look …
-
Podcast: Access affordability
is is the fourth episode in our Insights Uncovered: A Real-World Data Podcast Series, exploring the evolving landscape of real-world …
